Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity
Abstract Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type (mRNA, viral-vector, protein subunit vaccines) and dosing schedul...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01022-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846158818161983488 |
|---|---|
| author | Mathieu D’Souza Alexa Keeshan Christopher A. Gravel Marc-André Langlois Curtis L. Cooper |
| author_facet | Mathieu D’Souza Alexa Keeshan Christopher A. Gravel Marc-André Langlois Curtis L. Cooper |
| author_sort | Mathieu D’Souza |
| collection | DOAJ |
| description | Abstract Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type (mRNA, viral-vector, protein subunit vaccines) and dosing schedule. Data from a prospective cohort study collected over 34 months was used to evaluate the slope of antibody production and decay and neutralizing capacity following SARS-CoV-2 vaccination in individuals with and without obesity at baseline. Most participants were female (65.4%), white (92.4%), and received mRNA vaccines. 210 were obese and 697 non-obese. Sex and infection-acquired immunity were identified as effect modifiers for the relationship between obesity and COVID-19 vaccine humoral immunogenicity. No consistent influence of obesity on peak titres, titre retention, antibody isotype (IgG, IgM, IgA), or neutralization was identified when controlling for other key variables. It may not be necessary to consider this variable when developing SARS-CoV-2 vaccine dosing strategies. |
| format | Article |
| id | doaj-art-7dad72e7e4194c51ad6c6a8b21fd016c |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-7dad72e7e4194c51ad6c6a8b21fd016c2024-11-24T12:09:38ZengNature Portfolionpj Vaccines2059-01052024-11-019111010.1038/s41541-024-01022-8Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicityMathieu D’Souza0Alexa Keeshan1Christopher A. Gravel2Marc-André Langlois3Curtis L. Cooper4Ottawa Hospital Research InstituteOttawa Hospital Research InstituteSchool of Epidemiology and Public Health, Faculty of Medicine, University of OttawaDepartment of Biochemistry, Microbiology and Immunology, University of OttawaOttawa Hospital Research InstituteAbstract Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type (mRNA, viral-vector, protein subunit vaccines) and dosing schedule. Data from a prospective cohort study collected over 34 months was used to evaluate the slope of antibody production and decay and neutralizing capacity following SARS-CoV-2 vaccination in individuals with and without obesity at baseline. Most participants were female (65.4%), white (92.4%), and received mRNA vaccines. 210 were obese and 697 non-obese. Sex and infection-acquired immunity were identified as effect modifiers for the relationship between obesity and COVID-19 vaccine humoral immunogenicity. No consistent influence of obesity on peak titres, titre retention, antibody isotype (IgG, IgM, IgA), or neutralization was identified when controlling for other key variables. It may not be necessary to consider this variable when developing SARS-CoV-2 vaccine dosing strategies.https://doi.org/10.1038/s41541-024-01022-8 |
| spellingShingle | Mathieu D’Souza Alexa Keeshan Christopher A. Gravel Marc-André Langlois Curtis L. Cooper Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity npj Vaccines |
| title | Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity |
| title_full | Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity |
| title_fullStr | Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity |
| title_full_unstemmed | Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity |
| title_short | Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity |
| title_sort | obesity does not influence sars cov 2 humoral vaccine immunogenicity |
| url | https://doi.org/10.1038/s41541-024-01022-8 |
| work_keys_str_mv | AT mathieudsouza obesitydoesnotinfluencesarscov2humoralvaccineimmunogenicity AT alexakeeshan obesitydoesnotinfluencesarscov2humoralvaccineimmunogenicity AT christopheragravel obesitydoesnotinfluencesarscov2humoralvaccineimmunogenicity AT marcandrelanglois obesitydoesnotinfluencesarscov2humoralvaccineimmunogenicity AT curtislcooper obesitydoesnotinfluencesarscov2humoralvaccineimmunogenicity |